EASL Studio Podcast: Resmetirom: First approved drug for MASH, for whom and for how long?

EASL Podcasts - A podcast by European Association for the Study of the Liver

Try Bookbeat 60! days for free, click here

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

 Sponsored

This episode explores the approval of resmetirom for NASH, analysing its integration into clinical practice and patient eligibility. The experts also discuss the role of lifestyle interventions alongside resmetirom, the use of biomarkers for patient selection, treatment monitoring, and the expected landscape changes over the next five years.FacultyAleksander Krag (Moderator)Naim Alkhouri (Faculty)Sven Francque (Faculty)Amalia Gastaldelli (Faculty)Related episodesSeason 5 , Episode 2: Are 30% ...